arthritis news from FierceBiotech
NewsSPOTLIGHT: Anesiva inks $114M licensing deal
Transcription Factor Therapeutics has licensed the worldwide rights to Anesiva's NF-kB Decoy program, which includes the clinical drug candidate Avrina. NF-kB Transcription Factor Decoy inhibits Read more...
Targeted Genetics reports tgAAC94 data
Targeted Genetics is reporting results from an early-stage study of tgAAC94 for inflammatory arthritis. The drug uses a specially engineered virus to transport a gene. When working properly, the Read more...
Roche posts new data backing Actemra for RA
Roche has racked up more late-stage data backing Actemra as a new therapy for rheumatoid arthritis. Researchers say their fifth Phase III trial demonstrated that the therapy inhibited structural Read more...
Rituxan fails (again) in late-stage lupus trial
Genentech and Biogen Idec were taking it on the chin this morning after researchers announced that Rituxan had failed in a later-stage trial as a therapy for lupus. The failure won't harm the Read more...
UCB CEO plots strategy following Cimzia approval
Fresh off the FDA's approval of Cimzia for Crohn's disease, UCB chief executive Roch Doliveux forecast a swift regulatory success in Europe. Cimzia is one of the most closely watched late-stage Read more...
TxCell rounds up $16M in second round
France's TxCell has booked up €10.5 million (about $16 million) in a second round of venture funding. Previous investors Auriga Partners, AXA Private Equity, Bioam Gestion, CDC Innovation and Read more...
Cypress inks $75M deal to acquire Proprius
Cypress Bioscience has inked a deal to buy Proprius Pharmaceuticals in a deal that starts out at $37.5 million up front and goes up to $75 million if its gamble on new diagnostic technology pays off. Read more...
SPOTLIGHT: Humira approved for juvenile RA
Humira approved for juvenile RAThe FDA has approved Abbott's Humira as a treatment for juvenile rheumatoid arthritis. This marks the sixth approved indication for Abbott's monoclonal antibody. Read more...
EUSA, GSK ink $44M pre-clinical antibody deal
EUSA Pharma will keep about half of the $44 million in up front fees and milestones it is scheduled to receive from GlaxoSmithKline for a license covering a pre-clinical antibody targeted at lymphoma Read more...
| Press ReleasesPRESS RELEASE: Trubion Pharmaceuticals Shares Plunge After Arthritis Trial Results Trubion Pharmaceuticals Shares Plunge After Arthritis Trial Results SEATTLE, Sept. 10 -- Trubion Pharmaceuticals today announced preliminary analysis of results from a Phase IIb randomized, Read more... PRSS RELEASE: Pozen, AstraZeneca Announce Start of the PN 400 Phase III Program POZEN/AstraZeneca Announce Start of the PN 400 Phase III Program AstraZeneca to Pay an Immediate $30 Million Payment Under Revised Licensing Arrangement CHAPEL HILL, N.C.--(BUSINESS WIRE)--POZEN Read more... |
Get more arthritis coverage at:
Paid Research Reports
- Drug Repositioning Strategies - Serendipity by design
- eHealthInsight Series: Online Patient Recruitment Strategies - Optimizing the clinical trial process
- Pricing & Reimbursement - Seven Major Markets Update
- Innovative Clinical Trial Design and Management: Trends, success stories and impact upon R&D budgets
- The Emerging Role of Postmarketing Clinical Research: Regulatory issues, strategic drivers and overall trends